You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

57 Results
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Nov 2019
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Sep 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Curative, Palliative
Mar 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
ODB - General Benefit
    prednisone
Jan 2022
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
New Drug Funding Program
    Gemtuzumab Ozogamicin (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Nov 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
Jan 2022
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Adjuvant, Curative
Feb 2021
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative
Feb 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
New Drug Funding Program
    Gemtuzumab Ozogamicin (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Nov 2021

Pages